局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系_医学论文.docVIP

局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系_医学论文 局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系_医学论文 【摘要】 目的:研究局部晚期宫颈癌（LACC）细胞中 XPC、ERCC1 的表达与宫颈癌新辅助化疗（NACT）敏感性的关系，为临床克服和预示NACT耐受提供研究资料。方法:选取1999年6月至2006年6月间在浙江大学医学院附属妇产科医院住院、临床诊断为Ib2～IIb期的LACC患者77例，用免疫组化Envision 二步法显示宫颈癌细胞中XPC和ERCC1的表达水平，并分析其及各种临床和病理参数与疗效的关系。结果:77例患者中有效60例，有效率为77.9%(60/77)。XPC和ERCC1蛋白表达免疫组化定位均在细胞核，显示LACC中NACT无效者XPC蛋白的表达强于有效者，差异有显著性（P＜0.05）；NACT无效者ERCC1蛋白的表达强于有效者，差异有显著性（P＜0.01）。XPC、ERCC1蛋白表达存在高度一致，两者之间呈正相关（rs=0.418，P＜0.01）。结论:局部晚期宫颈癌新辅助化疗具有较高的临床应用价值；XPC 和ERCC1异常表达参与了局部晚期宫颈癌铂类耐受过程，异常上调表达的XPC 和ERCC1 蛋白可导致对铂类为基础NACT的耐受。 【关键词】 ERCC1 XPC 核苷酸剪切修复 局部晚期宫颈癌 新辅助化疗 Abstract: Objective: To analysis the protein expression of ERCC1、XPC and evaluate correlations among clinical, pathological, chemotherapy response variables and their prognostic value in locally advanced cervical cancer. Methods: Seventy seven continuous patients who was certified to be locally advanced cervical cancer were included. These patients underwent surgery after neoadjuvant chemotherapy from 1999 to 2006 in the Women Hospital，Zhejiang University，suffering from FIGO stage Ib2 or IIb disease of locally advanced cervical cancer. With immunohistochemical Envision two steps method staining of XPC and ERCC1 protein expression were performed on paraffin-embedded tissue sections. Results: XPC proteins expressed in the locally advanced cervical cancer cell nucleus. XPC proteins expression in the resistance for platinum-based chemotherapy of locally advanced cervical cancer were higher than those seen in the sensitivity for platinum-based chemotherapy of locally advanced cervical cancer, with X2 equal to 8.741 and P equal to 0.015, rs equal to -0.277 and P equal to 0.015. It was regarded as signiflcant difference. ERCC1 proteins overexpressed in the locally advanced cervical cancer cell nucleus. ERCC1 proteins expression in the resistance for platinum-based chemotherapy of locally advanced cervical cancer were higher than those seen in the sensitivity for platinum-based ch